Kornitzer Capital Management Inc. KS Buys 26,885 Shares of Hims & Hers Health, Inc. $HIMS

Kornitzer Capital Management Inc. KS boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 23.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 142,740 shares of the company’s stock after purchasing an additional 26,885 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Hims & Hers Health were worth $4,252,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of HIMS. Pictet Asset Management Holding SA boosted its holdings in shares of Hims & Hers Health by 4.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 30,530 shares of the company’s stock valued at $909,000 after buying an additional 1,346 shares during the last quarter. Kestra Advisory Services LLC grew its stake in Hims & Hers Health by 22.3% in the 3rd quarter. Kestra Advisory Services LLC now owns 20,900 shares of the company’s stock valued at $623,000 after buying an additional 3,811 shares during the last quarter. Greenfield Seitz Capital Management LLC increased its stake in shares of Hims & Hers Health by 4.6% during the third quarter. Greenfield Seitz Capital Management LLC now owns 385,366 shares of the company’s stock worth $11,480,000 after purchasing an additional 17,027 shares during the period. Kurv Investment Management LLC lifted its holdings in shares of Hims & Hers Health by 25.9% during the third quarter. Kurv Investment Management LLC now owns 65,274 shares of the company’s stock worth $1,945,000 after buying an additional 13,409 shares in the last quarter. Finally, Prosperitas Financial LLC bought a new stake in Hims & Hers Health in the 3rd quarter valued at about $2,649,000. 63.52% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 29,277 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $29.95, for a total value of $876,846.15. Following the transaction, the chief financial officer directly owned 236,527 shares of the company’s stock, valued at approximately $7,083,983.65. The trade was a 11.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05. Following the completion of the sale, the insider owned 313,964 shares of the company’s stock, valued at $8,649,708.20. The trade was a 7.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 133,905 shares of company stock valued at $3,826,977 in the last ninety days. 11.76% of the stock is owned by corporate insiders.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Under the agreement, eligible patients with prescriptions from Hims & Hers’ licensed providers can access FDA-approved Zepbound and Foundayo at Lilly’s self-pay prices without leaving the platform. The deal broadens Hims & Hers’ weight-loss offering and may help it attract patients seeking branded obesity medicines. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: Coverage of the collaboration described it as a catalyst for the stock, suggesting investors see the Lilly relationship as an important way to strengthen Hims & Hers’ position in the competitive weight-loss market. Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement
• Neutral Sentiment: Investors are also looking ahead to Hims & Hers’ Q3 results. A preview cited weight-loss demand, international expansion and subscriber growth as potential revenue drivers, with margins remaining an area to watch. HIMS’ Q3 Earnings: Can Weight Loss Momentum Drive Performance?

Hims & Hers Health Trading Down 0.2%

Shares of HIMS stock opened at $25.95 on Monday. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $42.70. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The firm has a market capitalization of $6.05 billion, a P/E ratio of -41.19 and a beta of 2.53. The stock’s fifty day simple moving average is $28.43 and its 200 day simple moving average is $26.94.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company’s revenue was up 38.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 earnings per share. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Morgan Stanley increased their target price on Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. TD Cowen increased their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Finally, Barclays decreased their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, August 21st. Three research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and a consensus target price of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products.

The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Founded in 2017, the company initially launched its Hims brand and later introduced Hers, expanding its services to a broader audience.